Big Pharma Pushes for New Antibiotic Funds to Fight SuperbugsBy
Group of 83 companies asks governments to join global action
Antibiotic development hampered by lower pricing for new drugs
Pharmaceutical giants including GlaxoSmithKline Plc and Merck & Co. are joining a large group of health-care companies to accelerate the development of drugs and diagnostics for “superbug” infections, trying to come up with a viable commercial model as an increasing number of bacteria become resistant to common antibiotics.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.